Executive summary

Executive summary: Scale-up strategies for late-stage cell therapies

Discover how Catalent can help you achieve efficiencies and develop a robust, reproducible manufacturing plan for late-stage and commercial launch.

As cell therapies reach late-stage clinical studies and regulatory decisions, strategies to help scale-up for commercial manufacturing, including meeting reduced timelines and the growing capacity demands, are critical to getting cell and gene therapies to patients. Discover how Catalent’s Manufacturing by Design (MbD) strategy can help achieve efficiencies, drive cost savings and develop and implement a robust, reproducible manufacturing plan for late-stage and commercial launch.